Edition:
India

Aimmune Therapeutics Submits BLA To FDA For Ar101 For The Treatment Of Peanut Allergy In Children And Adolescents Ages 4–17


Saturday, 22 Dec 2018 

Dec 21 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS SUBMITS BLA TO FDA FOR AR101 FOR THE TREATMENT OF PEANUT ALLERGY IN CHILDREN AND ADOLESCENTS AGES 4–17.